Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Consolidated Statements of Cash Flows

v3.25.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Operating activities      
Net loss for the year $ (3,313,346) $ (2,158,065) $ (7,718,882)
Items not affecting cash:      
Amortization 117,274 139,694 58,146
Fair value adjustment on derivative warrant liability (1,035,105) (3,641,403) (3,396,137)
Fair value of finders' warrants allocated to derivative liability     138,005
Share-based payments 122,527 120,984 487,940
Transaction costs on derivative warrant liability 279,031   797,598
Unrealized foreign exchange (gain) loss 34,178 (13,634) (6,391)
Changes in non-cash operating assets and liabilities:      
Accounts receivable 43,074 21,041 (41,098)
Prepaid expenses 208,166 142,654 622,595
Accounts payable and accrued liabilities (134,447) (1,194,436) 892,265
Cash flows from (used in) operating activities (3,678,648) (6,583,165) (8,165,959)
Investing activities      
Acquisition of intangible assets (38,924) (42,052) (26,005)
Acquisition of equipment   (4,311) (19,696)
Cash flows from (used in) investing activities (38,924) (46,363) (45,701)
Financing activities      
Pre-funded warrants and warrants exercised 16,573 296 64
Payment of lease obligation (69,723) (66,089) (20,410)
Cash share issuance costs (667,883) (295,251) (1,067,153)
Proceeds from issuance of equity instruments 3,500,542   4,999,640
Net cash flows from (used in) financing activities 2,779,509 (361,044) 3,912,141
Effect of foreign exchange (gain) loss on cash (35,953) 4,041 (136,146)
Decrease in cash (974,016) (6,986,531) (4,435,665)
Cash, beginning of year 3,447,665 10,434,196 14,869,861
Cash, end of year 2,473,649 $ 3,447,665 10,434,196
Supplemental Cash Flow and Non-Cash Investing and Financing Activities Disclosure      
Fair value of agent's warrants     185,738
Derivative warrant liability reclassified to share capital on exercise of warrants 5,244    
Recognition of right-of-use asset 96,998   $ 114,588
Deferred financing costs reclassified to share capital and transaction costs on derivative warrant liability $ 166,344